INTRODUCTION:

In the UK, "Delta plus" was dubbed from AY.4.2 and now is named VUI-21OCT-01which has been classified as a Variant Under Investigation (VUI) amidst the concern of its elevated growth rate¹.

The UK Health Security Agency changed its name to VUI-21OCT-01, which was named and changed from "Delta Plus".

They have been closely scrutinized in recent days after the evidence gathered by the data collected suggested that they spread more quickly than the dominant DV².

The Elderly eligible group, over 50s to get their immunity boosted up with the booster doses and continue to exercise caution, wear masks in crowded spaces and keep the windows and doors open to keep the room ventilated. One should isolate themselves at home if there are any symptoms and also is advised to take a PCR test, by a Public health expert³.

The Delta sub-lineage, `AY.4.2` is the newest mutation of the SARS-COV-2 virus variant of the infectious CV. According to the scientists based at Columbia University, there are more than 75 AY lineages of the CV species identified (table1). But out of all these 75 of the species of the CV, AY.4 is the one of the sub-variant which is branching out; heavily spreading all over the parts of UK and many other countries having this variant have noticed a rapid spread⁴.

There is a drastic spike in the DV in the past few months. According to the WHO epidemiological review, the new strain has been found in at least 42 other countries including India, The United States, the UK, Israel, and Russia. Researchers and scientists have raised a fear that this lineage belongs to a very fast-spreading DV and could be very infectious⁵.

In recent months, the DV AY.4.2 has been spotted in states across India. The variant was named and called a variant of concern (VoC), which is said to be more fatal and threatening than the DV, which has been traced to almost most of the world. Hence, it abates worries at the critical moment when vaccination exposure is still far from efficient, and many are returning to the pre-pandemic world⁶.

At present, not much is known about the new mutant or the lineage. Researchers and experts believe that it may have possibly originated from the DV, which could make it much more fatal than the existing strain of the CV, i.e., the DV. Also, little evidence shows that the current variant renders vaccine-driven antibodies ineffective or that the present immunity is ineffective. However, the information on the new mutant that has been investigated right now is that the lineage contains a bothering mutation, A1711V, which affects the virus's Nsp3 protein, which plays a multitude of roles in viral replication. It has two different mutations that impact the spike proteins of the virus⁷.

ABOUT COVID:

SARS-CoV 2 is a virus that is responsible for causing corona infection with different mutant species with almost all identical symptoms (table 2). Most people experience mild or moderate respiratory symptoms (table 3). No special or specific treatment is required for people experiencing mild to moderate respiratory illnesses. People with serious illnesses should have to go to the doctor for treatment. Patients with any underlying medical conditions like cardiovascular diseases, diabetes, chronic disease of the respiratory system, or cancer are more likely to develop serious and fatal conditions. Any patient having such complications and affected by COVID-19 might end up getting sick and might die at any possible age⁸.

This virus spreads similarly to that of influenza and tuberculosis and is usually seen as a communicable disease. It spreads through the mouth and nose of an infected person who coughs, sneezes, speaks, sings, or breathes. It is vital to follow proper respiratory etiquette to avoid contracting this virus, not only for oneself but also for others. Following the guidelines, the central government recommends six feet and social distancing. If any symptoms appear, the person should be isolated at home^9,10.

MUTATIONS:

Amino acid mutations of SARS-CoV-2 DV were plotted on a genome map of SARS-CoV-2 with a focus on Spike¹¹.

Table 1. Various types of variants and their mutation sites

Variant Types	Names of variants and their mutation sites
D614G	Aspartic acid-to-glycine substitution at position 614 is also shared with other highly transmissible variants like Alpha, Beta, and Gamma.
T478K	The exchange at position 478 is a threonine-to-lysine substitution.
L452R	The substitution at position 452, a leucine-to-arginine substitution.
T681R	The substitution at position 681, a proline-to-arginine substitution.
E484Q	The E484Q mutation is not present in the B.1.617.2 genome.

Table 2: Various corona variants and their lineages

Corona variants (WHO)	Lineages
Alpha	lineage B.1.1.7
E484K	WithB.1.1.7
Beta	lineage B.1.351
Gamma	lineage P.1
Delta	lineage P.1
Eta	lineage B.1.526
Iota	lineage B.1.526
Lambda	lineage C.37
Kappa	lineage B.1.617.1
Epsilon	lineage B.1.429, B.1.427, CAL.20C
Zeta	lineage P.2
Theta	lineage P.3

Table 3. Signs and symptoms of ay.4.2 DV

Symptoms	Old strain	New strain	Most common	Less common
Shortness of breath/ difficulty in breathing	û	û	û	ü
Loss of speech or mobility or confusion	û	û	û	ü
Chest pain	û	û	û	û
Fever	ü	û	ü	û
Cough	ü	û	ü	û
Tiredness	û	û	ü	û
Loss of taste or smell	ü	ü	ü	û
Aches and pains	û	ü	û	ü
Diarrhoea	û	ü	û	ü
Discolouration of fingers or toes	û	ü	û	ü
Skin rashes	û	ü	û	ü
Sore throat	û	ü	û	ü
Conjunctivitis	û	ü	û	ü
Headache	û	ü	û	ü

DIAGNOSIS:

All variants of COVID-19 are diagnosed with a medical history that includes any recent known exposure to COVID-19 and a physical exam to check for symptoms of COVID-19. If COVID-19 is suspected, tests used to diagnose the virus include.

A test or identification that a person had a COVID-19 infection in the past may be done, but it does not diagnose the current infections as it takes approximately three weeks to produce a set of antibodies to the virus infection that befell in the body. COVID-19 regular test kits do not test for the different variants happening. Testing for the various variants requires expertise that can test for the various variants, which requires genomic sequencing (table 4). Not all labs are equipped with such techniques¹². Prevalence can be determined by the state health department by running a few tests for a particular variant (figure 1).

Table 4. Various species spike mutations and their attributes

	B.1.526	B.1.526.1	B.1.525	P.2	B.1.617	B.1.617.1	B.1.67.2	B.1.671.3
First Detected	New York	New York	UK/Nigeria	Brazil	India	India	India	India
No. of spike mutations	3-7	6-8	8	3-4	3	7-8	9-10	7
Receptor binding domain mutations	(S477N) (E484K)	L452R	E484K	E484K	L452RE484Q	L452RE484Q	L452RT478K	L452RE484Q
Attributes	Reduced antibody efficacy	Potential reduced antibody efficacy		Potential reduced antibody efficacy	Potential reduced antibody efficacy	Potential reduced antibody efficacy
Attributes	Reduced neutralization convalescent or vaccine sera	Vaccines have the potential to reduce neutralization		Reduced neutralization by the vaccine is possible	Vaccines could potentially reduce neutralization	Reduced neutralization of vaccine by the vaccine will be possible

Figure 1. Diagnostic tests for CoV-19.

Prevention:

The following are strict steps to be taken to avoid the spreading of CoV-19^13,14.

· Wash your hands with soap and water for at least 20 sec, especially after blowing your nose, coughing, and sneezing.

· During the preparation of food, and after and before eating food, washing hands is important.

· During handling the mask, it is advised to be very careful and a prior and after hand wash is recommended.

· While changing the baby's diaper, hygiene and precautions must be taken.

· When looking after a sick patient, it is advised to be very careful.

· Proper handwashing is advised after meeting or touching a pet.

· Hand sanitizers are preferred second to hands and water. When it is not readily available, hand sanitizers are preferred that contain at least 60% alcohol. Until the hands feel dry, rub them together by covering all the surfaces of the hands.

· The face and the mouth should be covered properly with a tissue or a mask, and it should be disposed of properly in the bins without any contact or contamination.

· When someone is sick or tests positive for COVID-19, disinfect the frequently touched places.

· Before disinfection, clean the surface with soap and water.

· A routine monitoring check-up is a must.

· If you are feeling unwell or have any symptoms, stay home. If the symptoms seem to worsen, go to the doctor for a consultation. Only move out of the house when recovered.

Outcomes:

According to scientists and researchers, AY.4.2, this CV variant, has a faster onset of spread and infection. This variant has similar signs and symptoms to those of the DV of the CV. If any symptoms happen to appear in any person, they are advised to consult a doctor, get themselves tested for COVID-19, and isolate themselves until they are recovered¹⁵.

CONCLUSION:

According to scientists and researchers, AY.4.2, this CV variant, has a faster onset of spread and infection. This variant has similar signs and symptoms to those of the DV of the CV.

Thus, after determining the fatality and potential severity of the variant, it is recommended that the public maintain the social distance in crowded places while also taking precautionary measures to avoid meeting the virus. If any symptoms happen to appear in any person, they are advised to consult a doctor, get themselves tested for COVID-19, and isolate themselves until they are recovered.

ACKNOWLEDGMENTS:

The authors are thankful to the college management for their encouragement.

CONFLICT OF INTEREST:

None.

REFERENCES:

1. Kannan SR, Spratt AN, Cohen AR, et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. 2021;124:102715.

2. Malabadi RB, Kolkar KP, Meti NT, Chalannavar RKJIJoR, g SI. Outbreak of Coronavirus (SARS-CoV-2) Delta variant (B. 1.617. 2) and Delta Plus (AY. 1) with fungal infections, Mucormycosis: Herbal medicine treatment. 2021;8(6):59-70.

3. Thalluri SJJoPGNP. A study of the isotopes 159Dy and 161Er using the surface delta plus quadrupole interaction. 1981;7(2):181.

4. Burki TKJTLRM. Lifting of COVID-19 restrictions in the UK and the Delta variant. 2021;9(8):e85.

5. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. 2021:1-8.

6. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. 2021.

7. Sapkal GN, Yadav PD, Sahay RR, et al. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals. 2021;28(7):taab119.

8. Chinthaginjala H, Ahad HA, Sumanth G, Shaik M, Dasari RRJIJoP, Research P. Hunting Hantavirus: A Quick Guide for Healthcare Professionals before It Invades the Globe unlike COVID-19. 2020:1-6.

9. Ahad HA, Haranath C, Roy D, Dharani BS, Raghav R, Dasari SR. A Quick Reference to The Diagnosis Test for COVID-19: Guide to Every Healthcare Professional in Global Emergencies.

10. Kumar YB, Ahad HA, Haranath C, Sumanth G, Pasupuleti DS, Reddy SSJIJLSPR. Platelet Rich Plasma Therapy: A quick note for every health care professional. (2020).10(5):P84-89.

11. Ahad HA, Chinthaginjala H, Abdelaziz MAA, Rahamathulla SJdo. Jyothi Vinay Krishna et al Yellow Fungus emerging cases in India during the second wave of COVID-19”. J Pharmacy and Drug Innovations, 2 (5); DOI: http. 2021.

12. Shoenfeld YJAr. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. 2020;19(6):102538.

13. Luo H, Tang Q-L, Shang Y-X, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. 2020;26(4):243-250.

14. Sajed AN, Amgain KJEJoMS. Corona virus disease (COVID-19) outbreak and the strategy for prevention. 2020;2(1):1-3.

15. Basiri MRJJPP. Theory about treatments and morbidity prevention of corona virus disease (Covid-19). 2020;8(3):89-90.

Received on 05.04.2022 Modified on 02.05.2022

Res. J. Pharmacology and Pharmacodynamics.2022;14(3):151-154.

DOI: 10.52711/2321-5836.2022.00025